In a phase 3 trial of 124 adolescents and adults with C3 glomerulopathy or primary immune-complex MPGN, pegcetacoplan reduced proteinuria at week 26 vs placebo (geometric mean change −67.2% vs 2.9%; relative reduction 68.1%), without more adverse events.
RCTn = 124
Fakhouri et al. Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN